Avalon Investment & Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Avalon Investment & Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,340	Closed	-$1.08M	–	369
2021 Q2	$1.08M	Sell	5,340 -290	-5%	-$60.7K	0.02%	236
2021 Q1	$1.21M	Sell	5,630 -251	-4%	-$55.1K	0.03%	223
2020 Q4	$1.39M	Sell	5,881 -31,232	-84%	-$7.17M	0.03%	224
2020 Q3	$10.1M	Sell	37,113 -586	-2%	-$162K	0.22%	117
2020 Q2	$10.9M	Sell	37,699 -2,459	-6%	-$667K	0.25%	114
2020 Q1	$9.56M	Buy	+40,158	New	+$9.21M	0.24%	117

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Avalon Investment & Advisory's VRTX Position: Q3 2021 in Review

Avalon Investment & Advisory sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 5,340 shares — an estimated $1.08M sold.

Avalon Investment & Advisory first reported a position in VRTX in Q1 2020 and held it in 6 quarters. The position peaked at $10.9M in Q2 2020. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Avalon Investment & Advisory reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Avalon Investment & Advisory sold 5,340 Vertex Pharmaceuticals shares in Q3 2021, an estimated $1.08M.
Avalon Investment & Advisory first reported a position in Vertex Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Avalon Investment & Advisory's Vertex Pharmaceuticals position peaked at $10.9M in Q2 2020.
933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Avalon Investment & Advisory's 13F filing for Q3 2021, filed 8 Nov 2021.